Supplementary Table S1 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Increased α-fetoprotein (AFP) levels have been reported to predict a poor prognosis in hepatocellular carcinoma (HCC). We assessed the mechanism of AFP involvement in the progression of HCC and determ
Purpose A variety of targeted drug were developed and proved effective and safe in clinical trials. Our study aims to compare the efficacies and safety of different targeted drugs in advanced hepatoce
Additional file 7. All adverse events and serious adverse events; N (%). Frequencies of all adverse events and serious adverse events reported from each trial by each trial arm.
Crystal structure of BRAF/MEK1 complex with NST-628 and an active RAF dimer Descriptor: 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, Dual specificity mitogen-activated protein kinase kina
*p-value from a comparison of the three treatment groups using Fisher's exact test. % refers to the proportion of children who reported an adverse event on any occasion after drug administration.
